Kalvista Pharmaceuticals Inc
KALV13.310USD
+0.100+0.76%
收盤 08/04, 16:00（美東）報價延遲15分鐘
662.33M總市值
虧損本益比TTM
關於 Kalvista Pharmaceuticals Inc 公司
KalVista Pharmaceuticals, Inc. 是一家臨牀階段製藥公司。該公司專注於發現、開發和商業化具有重大未滿足需求的疾病的藥物療法。其候選產品是 sebetralstat，一種血漿激肽釋放酶抑制劑，正在開發用於遺傳性血管性水腫 (HAE)。Sebetralstat 旨在爲患有 HAE 的人提供一種藥物，可以作爲謹慎的口服劑量服用，以便隨時治療 HAE 發作，包括在發作完全發展之前的最早跡象。Sebetralstat 通過針對激肽釋放酶-激肽系統 (KKS) 級聯起作用，選擇性抑制血漿激肽釋放酶及其驅動 HAE 發作的不受控制的活動。該公司還在設計一種口服因子 XIIa 抑制劑用於 HAE 預防，使 KalVista 能夠解決 HAE 疾病管理的全方位問題。因子 XIIa 抑制劑計劃旨在解決其他治療領域，包括炎症和血栓形成。
公司簡介
公司代碼KALV
公司名稱Kalvista Pharmaceuticals Inc
上市日期Apr 09, 2015
CEOMr. Benjamin L. (Ben) Palleiko
員工數量270
證券類型Ordinary Share
年結日Apr 09
公司地址55 Cambridge Pkwy Ste 901E
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02142-1234
電話18579990075
網址https://www.kalvista.com/
公司代碼KALV
上市日期Apr 09, 2015
CEOMr. Benjamin L. (Ben) Palleiko
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
369.60K
+17.30%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
127.94K
+30.30%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
113.03K
+9.80%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Mr. Edward W. Unkart, CPA
Mr. Edward W. Unkart, CPA
Independent Director
Independent Director
--
--
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Stuart
Ms. Nancy Stuart
Independent Director
Independent Director
--
--
Mr. William Fairey
Mr. William Fairey
Independent Director
Independent Director
--
--
Mr. Brian Piekos
Mr. Brian Piekos
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
369.60K
+17.30%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
127.94K
+30.30%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
113.03K
+9.80%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Mr. Edward W. Unkart, CPA
Mr. Edward W. Unkart, CPA
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月3日 週日
更新時間: 8月3日 週日
持股股東
股東類型
持股股東
持股股東
佔比
VR Adviser, LLC
13.47%
Tang Capital Management, LLC
9.89%
Suvretta Capital Management, LLC
9.84%
Frazier Life Sciences Management, L.P.
9.78%
Vestal Point Capital, LP
9.51%
Other
47.51%
持股股東
持股股東
佔比
VR Adviser, LLC
13.47%
Tang Capital Management, LLC
9.89%
Suvretta Capital Management, LLC
9.84%
Frazier Life Sciences Management, L.P.
9.78%
Vestal Point Capital, LP
9.51%
Other
47.51%
股東類型
持股股東
佔比
Hedge Fund
38.74%
Investment Advisor
27.47%
Investment Advisor/Hedge Fund
19.16%
Venture Capital
13.78%
Private Equity
9.78%
Research Firm
3.12%
Individual Investor
1.79%
Pension Fund
0.16%
Bank and Trust
0.08%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
291
60.09M
120.29%
-6.33M
2025Q1
300
56.85M
114.35%
-10.03M
2024Q4
295
57.02M
115.39%
-4.36M
2024Q3
292
50.23M
115.93%
-11.73M
2024Q2
292
49.87M
116.71%
-8.51M
2024Q1
293
49.24M
116.93%
-4.79M
2023Q4
269
38.06M
110.17%
-12.86M
2023Q3
274
38.57M
113.73%
-12.48M
2023Q2
275
36.74M
108.90%
-12.50M
2023Q1
287
35.85M
106.52%
-13.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
VR Adviser, LLC
6.73M
13.53%
+25.00K
+0.37%
Apr 09, 2025
Tang Capital Management, LLC
4.94M
9.94%
+47.95K
+0.98%
Mar 31, 2025
Suvretta Capital Management, LLC
4.91M
9.88%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.89M
9.83%
--
--
Mar 31, 2025
Vestal Point Capital, LP
4.75M
9.56%
-18.71K
-0.39%
Mar 31, 2025
Capital World Investors
3.18M
6.39%
-196.48K
-5.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.7%
+204.53K
+7.78%
Mar 31, 2025
The Vanguard Group, Inc.
2.30M
4.62%
+43.35K
+1.92%
Mar 31, 2025
SilverArc Capital Management, LLC
1.70M
3.42%
+1.09M
+177.53%
Mar 31, 2025
Woodline Partners LP
1.62M
3.25%
+329.07K
+25.54%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.13%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
Fidelity Enhanced Small Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.78%
Invesco NASDAQ Future Gen 200 ETF
佔比0.43%
SPDR S&P Biotech ETF
佔比0.13%
iShares Micro-Cap ETF
佔比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.08%
Fidelity Enhanced Small Cap ETF
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
iShares Biotechnology ETF
佔比0.05%
iShares Russell 2000 Growth ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
